Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance
Cutis · 01.05.2026 · 5 (117)
DOI: 10.12788/cutis.1411 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cutis, erschienen am 01.05.2026. Verfasst von Camille Moeckel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Penn State College of Medicine, Hershey, Pennsylvania. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pemphigoid, Bullous, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Penn State College of Medicine, Hershey, Pennsylvania.
Zitieren
APA
Moeckel, C., & Ferguson, S. (2026). Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance. Cutis, 5(117). https://doi.org/10.12788/cutis.1411
Vancouver
Moeckel C, Ferguson S. Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance. Cutis. 2026;5(117). doi:10.12788/cutis.1411
BibTeX
@article{Moeckel2026,
author = {Moeckel, Camille and Ferguson, Sara},
title = {Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance},
journal = {Cutis},
year = {2026},
volume = {5},
number = {117},
doi = {10.12788/cutis.1411}
}
EUVIMED